Magnetic Drug Targeting

Magnetism in Medicine: A Handbook: Second Edition

Volumn , Issue , 2007, Pages 596-605

  Alexiou, Christoph ^a   Jurgons, Roland ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Background and history of magnetic drug targeting; Current applications of magnetic drug targeting; Magnetic drug targeting; Regional chemotherapies for cancer treatment

Indexed keywords

EID: 77955304209     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527610174.ch4h     Document Type: Chapter

References (49)

1. Alexiou, C., Arnold, W., Klein, R., Parak, F., Hulin, P., Bergemann, C., Erhardt, W., Wagenpfeil, S., and Lübbe, A.S. (2000). Locoregional cancer treatment with magnetic drug targeting. Cancer Res., 60, 6641-6648.
2. Alexiou, C., Arnold, W., Hulin, P., Klein, R., Renz, H., Parak, F.G., Bergemann, C., and Lübbe, A.S. (2001). Magnetic mitoxantrone nanoparticle detection by histology, x-ray and MRI after magnetic drug targeting. J. Magn. Magn. Mater., 225, 187-193.
3. Alexiou, C., Schmidt, A., Hulin, P., Klein, R., Bergemann, C., and Arnold, W. (2002). Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J. Magn. Magn. Mater., 252, 363-366.
4. Alexiou, C., Jurgons, R., Schmid, R., Bergemann, C., Henke, J., Erhardt, W., Huenges, E., and Parak, F.G. (2003). Magnetic drug targeting-Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantron after locoregional cancer treatment. J. Drug Target., 11, 139-149.
5. Alexiou, C., Jurgons, R., Schmid, R.J., Hilpert, A., Bergemann, C., Parak, F.G., and Iro, H. (2005). In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles. J. Magn. Magn. Mater., 293, 389-393.
6. Alexiou, C., Schmid, R.J., Jurgons, R., Kremer, M., Wanner, G., Bergemann, C., Huenges, E., Nawroth, T., and Parak, F.G. (2006). Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur. Biophys. J., 35, 446-450.
7. Alksne, J.F., Fingerhut, A., and Rand, R. (1966). Magnetically controlled metallic thrombosis of intracranial aneurysms. Surgery, 60, 212-218.
8. Allen, L.M., Kent, J., Wolfe, C., Ficco, C., and Johnson, J. (1997). MTCTM: a magnetically targetable drug carrier for paclitaxel. In: Häfeli, U., Schü tt, W., Teller, J., and Zborowski, M. (Eds.), Scientific and Clinical Applications of Magnetic Carriers, Plenum Press, New York, London, pp. 481-494.
9. Arap, W., Haedicke, W., Bernasconie, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H.M., Bredesen, D.E., Pasqualini, R., and Ruoslathi, E. (2002). Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA, 99, 1527-1531.
10. Collins, J.M. (1984). Pharmacological rationale for regional drug delivery. J. Clin. Oncol., 2, 498-505.
11. Gerlowski, L.E. and Jain, R.K. (1986). Microvascular permeability of normal and neoplastic tissues. Microvasc. Res., 31, 288-299.
12. Goodwin, S.C., Bittner, C.A., Peterson, C.L., and Wong, G. (2001). Single dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol. Sci., 60, 177-183.
13. Gupta, P.K. (1990). Drug targeting in chemotherapy: a clinical perspective. J. Pharm. Sci., 79, 949-962.
14. Gupta, P.K. and Hung, C.T. (1990a). Comparative disposition of adriamycin delivered via magnetic albumin microspheres in presence and absence of magnetic fields in rats. Life Sci., 46, 471-484.
15. Gupta, P.K. and Hung, C.T. (1990b). Targeted delivery of low dose doxorubicin hydrochloride administered via magnetic albumin microspheres in rats. J. Microencap., 7, 85-92.
16. Gupta, P.K. and Hung, C.T. (1994). Magnetically controlled targeted chemotherapy. In: Willmott, N. and Daly, J. (Eds.), Microspheres and Regional Cancer Therapy, CRC Press, Boca Raton, Florida, pp. 71-116.
17. Haber, E. (1994). Antibody targeting as a strategy in thrombolysis. In: Kaw, B.A., Narula, J., and Strauss, H.W. (Eds.), Monoclonal antibodies in cardiovascular diseases, Lea & Febiger, Malvern, pp. 187-197.
18. Häfeli, U.O. (2001). Radioactive magnetic microspheres In: Arshady, R. (Ed.), Microspheres, Microcapsules and Liposomes: Magneto-and Radio-Pharmaceuticals, 3, Citus Books, London, pp. 559-584.
19. Häfeli, U.O., Pauer, G.J., Roberts, W.K., Humm, J.L., and Macklis, R.M. (1997). Magnetically targeted microspheres for intracavitary and intraspinal 90Y radiotherapy. In: Häfeli, U., Schü tt, W., Teller, J., and Zborowski, M. (Eds.), Scientific and Clinical Applications of Magnetic Carriers, Plenum Press, New York, London, pp. 501-516.
20. Hilal, S.K., Michelsen, W.J., Driller, J., and Leonard, E. (1974). Magnetically guided devices for vascular exploration and treatment. Radiology, 113, 529-534.
21. Kato, T., Nemoto, R., Mori, H., Unno, K., Goto, A., and Homma, M. (1980). An approach to magnetically controlled cancer chemotherapy. J. Jap. Soc. Cancer Ther., 15, 876-880.
22. Kato, T., Nemoto, R., Mori, H., Abe, R., Unno, K., Goto, A., Murota, H., Harada, M., Kawamura, K., and Homma, M. (1981). An approach to magnetically controlled cancer chemotherapy. J. Jap. Soc. Cancer Ther., 16, 1351-1357.
23. Kramer, P.A. (1974). Albumin microspheres vehicles for archiving specificity in drug delivery. J. Pharm. Sci., 63, 1646-1647.
24. Kuznetsov, A., Harutyunyan, A.R., Dobrinski, E.K., Filippov, V.I., Malenkov, A.G., Vanin, A.F., and Kuznetsov, O.A. (1997). Ferro-carbon particles: Preparation and clinical applications. In: Häfeli, U., Schütt, W., Teller, J., and Zborowski, M. (Eds.), Scientific and Clinical Applications of Magnetic Carriers, Plenum Press, New York, London, pp. 379-389.
25. Leveugle, B., Mann, D., Madiyalakan, R., and Noujaim, A.A. (2000). Therapeutic antibodies for prostate cancer. IDrugs, 3, 1191-1198.
26. Lübbe, A.S., Bergemann, C., Huhnt, W., Fricke, T., Riess, H., Brock, J.W., and Huhn, D. (1996a). Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56, 4694-4701.
27. Lübbe, A.S., Bergemann, C., Riess, H., Schriever, F., Reichardt, P., Possinger, K., Matthias, M., Dorken, B., Herrmann, F., Gurtler, R., Hohenberger, P., Haas, N., Sohr, R., Sander, B., Lemke, A.J., Ohlendorf, D., Huhnt, W., and Huhn, D. (1996b). Clinical experiences with magnetic drug targeting: a Phase I study with 40-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56, 4686-4693.
28. Lübbe, A.S., Bergemann, C., and Alexiou, C. (2000). Magnetically-controlled drug targeting for cancer treatment. Recent Res. Devel. Cancer, 2, 183-191.
29. Lübbe, A.S., Alexiou, C., and Bergemann, C. (2001). Clinical applications of magnetic drug targeting. J. Surg. Res., 95, 200-206.
30. Morris, R.M., Poore, G.A., Howard, D.P., and Sefranka, J.A. (1984). Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in yoshida-bearing rats. In: Davis, S.S., Illum, L., McVie, J.G., and Tomlinson, E. (Eds.), Microspheres and Drug Therapy. Pharmaceutical, immunological and medical aspects, Elsevier, New York, pp. 439-440.
31. Neglia, J.P., Friedmann, D.L., and Yasui, Y. (2001). Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J. Natl. Cancer. Inst., 93, 618-629.
32. Nobuto, H., Sugita, T., Kubo, T., Shimose, S., Yasunaga, Y., Murakami, T., and Ochi, M. (2004). Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int. J. Cancer, 109, 627-635.
33. Poste, G. and Kirsh, R. (1983). Site specific (targeted) drug delivery in cancer therapy. Biotechnol., 10, 869-885.
34. Rahman, Y., Cerny, E.A., Tallaksen, S.L., Wright, B.J., Nance, S.O., and Thompson, J.F. (1974). Liposomes-encapsulated actinomycin D: potential in cancer chemotherapy. Proc. Soc. Exp. Biol. Med., 146, 1173-1176.
35. Rudge, S., Peterson, C., Vessely, C., Koda, J., Stevens, S., and Catterall, L. (2001). Adsorption and desorption of chemotherapeutic drugs from magnetically targeted carrier (MTC). J. Control. Release, 74, 335-340.
36. Sachdeva, M.S. (1998). Drug targeting systems for cancer therapy. Expert. Opin. Investig. Drugs, 7, 1849-1864.
37. Scherer, F., Anton, M., Schillinger, U., Henke, J., Bergemann, C., Kruger, A., Gänsbacher, B., and Plank, C. (2002). Magnetofection enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther., 9, 102-109.
38. Shinkai, M., Suzuki, M., Iijima, S., and Kobayashi, T. (1994). Antibody-conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia Biotechnol Appl. Biochem., 21, 125-137.
39. Storm, G., Belliot, S.O., Daemen, T., and Lasic, D.D. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev., 17, 31-48.
40. Torchilin, V.P. (2000). Drug targeting. Eur. J. Pharm. Sci., 11, 81-91.
41. Torchilin, V.P. and Trubetskoy, V.S. (1995). Which polymer can make nanoparticulated drug carriers long circulating? Adv. Drug Deliv. Rev., 16, 141-155.
42. Torchilin, V.P., Zhou, F., and Huang, L. (1993). pH-sensitive liposomes. Liposome Res., 3, 201-205.
43. Viroonchatapan, E., Ueno, M., Sato, H., Adachi, I., Nagae, H., Tazawa, K., and Horikoshi, I. (1995). Preparation and characterization of dextran magnetiteincorporated thermosensitive liposomes: an on-line flow system for quantifying magnetic responsiveness. Pharm. Res., 12, 1176-1183.
44. Widder, K.J., Senyei, A.E., and Scarpelli, D.G. (1978). Magnetic microspheres: a model system for site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med., 158, 141-146.
45. Widder, K.J., Senyei, A.E., and Ranney, D.F. (1979). Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. In: Gavattini, S., Goldin, A., Howking, F., Kopin, I.J., and Schnitzer, R.J. (Eds.), Advances in Pharmacology and Chemotherapy, Academic Press, New York, pp. 213-239.
46. Widder, K.J., Morris, R.M., Poore, G.A., Howard, D.P., and Senyei, A.E. (1983). Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in yoshida sarcoma bearing rats. Eur. J. Cancer Clin. Oncol., 19, 135-139.
47. Wilson, M.W., Kerlan, R.K., Fidelman, N.A., Venook, A.P., La Berge, J.M., Koda, J., and Gordon, R.L. (2004). Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients. Radiology, 230, 287-293.
48. Yatvin, M.B., Kreutz, W., Horwitz, B.A., and Shinitzky, M. (1980). pH-sensitive liposomes: possible clinical implications. Science, 210, 1253-1255.
49. Zacharski, L.R., Ornstein, D.L., Gabazza, E.C., D'Alessandro-Gabazza, C.N., Brugarolas, A., and Schneider, J. (2002). Treatment of malignancy by activation of the plasminogen system., Semin. Thromb. Hemost., 28, 5-18.